BFI Co., LLC, which is identified as a ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), completed a series of stock disposals between March 24 and March 26, 2026, totaling 15,500 shares of Class A Common Stock for approximately $1.16 million. The trades were executed under a pre-arranged 10b5-1 trading plan and spanned trade prices from $52.8772 to $57.1702.
The background to the sales is notable: PAHC shares have risen 161% over the past 12 months and are trading near a 52-week high of $57.62, according to InvestingPro data. That same platform’s Fair Value analysis indicates the stock may be overvalued at current levels.
Details of the transactions are disclosed in a Form 4 filing with the Securities and Exchange Commission.
On March 24, BFI Co. sold two tranches. The first was 6,523 shares at a weighted average price of $52.8772, with individual executions ranging from $52.44 to $53.435. The second tranche that day was 517 shares at a weighted average price of $53.5886, with trade prices between $53.53 and $53.70.
Activity continued on March 25 with three separate disposals. BFI Co. sold 1,572 shares at an average price of $55.2822, with pricing between $54.69 and $55.65. It also sold 4,916 shares at an average price of $56.0041, in a range between $55.76 and $56.745, and 552 shares at an average price of $56.8584, with the individual trades occurring between $56.76 and $56.91.
The sequence concluded on March 26, when the entity sold 6,760 shares at a weighted average price of $56.7852, with trades ranging from $56.12 to $57.06, and an additional 280 shares at an average price of $57.1702, in a range between $57.14 and $57.24.
After these sales, BFI Co., LLC directly holds 52,200 shares of Phibro Animal Health Corp Class A Common Stock.
The Form 4 also notes the relationship between BFI Co., LLC and Jack Bendheim. Mr. Bendheim is identified as a director, officer, and ten percent owner of Phibro Animal Health Corp and is described as exercising voting and dispositive power over BFI Co., LLC. Accordingly, he may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Separately, Mr. Bendheim directly holds 16,840 shares.
Recent company performance
Phibro Animal Health Corporation reported fiscal second-quarter 2026 results that exceeded consensus expectations. The company posted earnings per share of $0.87, above the forecasted $0.68 - a 27.94% outperformance relative to the estimate. Revenue for the quarter was $373.9 million, surpassing the anticipated $355.24 million by 5.25%.
Those results are cited as indicators of the company’s recent operating strength and were reflected in a positive market response to the quarterly release.
Context and interpretation
The sales by BFI Co., LLC were carried out through a pre-established 10b5-1 plan, as stated in the SEC filing. The combination of significant insider-related selling, a pronounced year-over-year share-price gain of 161%, and trading near the 52-week high are the principal contextual elements documented in the filing and related market-data notes. InvestingPro’s Fair Value assessment suggesting potential overvaluation is also cited in the public data referenced in the filing.
The filing provides precise transaction-level data and the post-transaction holdings of BFI Co., LLC and Mr. Bendheim, enabling investors to reconcile insider ownership and recent liquidity events against the company’s published quarterly performance.
This report limits itself to the facts disclosed in the SEC filing and company quarter results; it does not attempt to draw conclusions beyond the documented transactions and reported financial figures.